title: [Eribulin in the treatment for metastatic breast cancer].
abstract: Eribulin is a novel antimicrotubule drug, which is approved in the second line treatment of advanced breast cancer in patients who received anthracyclines and taxanes. The article presents the results of two huge phase III clinical trials (301, 305) and their pooled analysis. Eribulin monotherapy demonstates staistically significant improved overall survival compared to standart treatments (15.2 mnths vs 12.8 mnths, p = 0.03 in pooled analysis). Certain subgroups of patients--Her2-negative and triple-negative have the most survival benefit. According to own experience with Eribulin inside the clinical trials, presented in the article, the drug is effective and well tolerated even by older patients.
authors.forename: L V
authors.initials: LV
authors.lastname: Manzyuk
authors.forename: E I
authors.initials: EI
authors.lastname: Kovalenko
authors.forename: E
authors.initials: E
authors.lastname: Artamonova
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D004334:Drug Administration Schedule; D005260:Female; D005663:Furans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D053208:Kaplan-Meier Estimate; D007659:Ketones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D015201:Meta-Analysis as Topic; D008870:Microtubules / Q000187:drug effects*; D009503:Neutropenia / Q000139:chemically induced; D012720:Severity of Illness Index; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides